NCT00328497View on ClinicalTrials.gov

A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2009

Conditions
Carcinoid Tumor
Interventions
DRUG

Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)

Panzem NCD 1,000 mg, four times daily for 28 consecutive days bevacizumab 5 mg/kg intravenous bolus on Day 1 and Day 15

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

CASI Pharmaceuticals, Inc.

INDUSTRY

NCT00328497 - A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors | Biotech Hunter | Biotech Hunter